Oleanolic acid (Synonyms: Astrantiagenin C, Caryophyllin, Giganteumgenin C, Gledigenin 1, NSC 114945, Oleanoic Acid, Virgaureagenin B) |
| Catalog No.GN10184 |
Oleanolic acid is a natural pentacyclic triterpenoid known for its effectiveness in treating hepatitis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 508-02-1
Sample solution is provided at 25 µL, 10mM.
Oleanolic acid is a natural pentacyclic triterpenoid known for its effectiveness in treating hepatitis. Additionally, it demonstrates antitumor effects across various types of cancers [1-3].
Oleanolic acid, at concentrations of 50 μM, 65 μM, and 80 μM, when administered for 24 or 48 hours, enhanced the ability of regorafenib to suppress the growth of PLC cells, particularly at doses of 65 μM or 80 μM[4]. Oleanolic acid, at concentrations of 2 μM, 4 μM, and 8 μM administered over 48 hours, acts as an activator of Nrf2. It exhibits a dose-dependent attenuation of TGF-β1-induced epithelial-mesenchymal transition (EMT) in NRK-52E cells [5]. Furthermore, oleanolic acid at a concentration of 50 μM, when applied for 6 hours, induces prostacyclin release in human coronary smooth muscle cells (SMC) through a Cox-2-dependent mechanism[6].
Oleanolic acid(50 mg/kg/d; i.g; 2weeks) exerts anti-EMT effect in vivo and enhances the antitumor effect of regorafenib[4]. Oleanolic acid(10-100 mg/kg; ip) demonstrated significant anti-epileptogenic potential in pentylenetetrazole-induced seizures[7].
References:
[1]. Pollier J, Goossens A. Oleanolic acid. Phytochemistry. 2012 May;77:10-5. doi: 10.1016/j.phytochem.2011.12.022. Epub 2012 Feb 28. PMID: 22377690.
[2]. Ma W, Wang DD, et,al. Caveolin-1 plays a key role in the oleanolic acid-induced apoptosis of HL-60 cells. Oncol Rep. 2014 Jul;32(1):293-301. doi: 10.3892/or.2014.3177. Epub 2014 May 15. PMID: 24842472.
[3]. Žiberna L, Šamec D, et,al. Oleanolic Acid Alters Multiple Cell Signaling Pathways: Implication in Cancer Prevention and Therapy. Int J Mol Sci. 2017 Mar 16;18(3):643. doi: 10.3390/ijms18030643. PMID: 28300756; PMCID: PMC5372655.
[4]. Wang H, Zhong W, et,al. Oleanolic Acid Inhibits Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization. Mol Cancer Ther. 2019 Jan;18(1):62-74. doi: 10.1158/1535-7163.MCT-18-0448. Epub 2018 Oct 8. PMID: 30297361.
[5]. He WM, Yin JQ, et,al. Oleanolic acid attenuates TGF-β1-induced epithelial-mesenchymal transition in NRK-52E cells. BMC Complement Altern Med. 2018 Jul 4;18(1):205. doi: 10.1186/s12906-018-2265-y. PMID: 29973206; PMCID: PMC6031099.
[6]. Martínez-González J, Rodríguez-Rodríguez R, et,al. Oleanolic acid induces prostacyclin release in human vascular smooth muscle cells through a cyclooxygenase-2-dependent mechanism. J Nutr. 2008 Mar;138(3):443-8. doi: 10.1093/jn/138.3.443. PMID: 18287347.
[7]. Akünal Türel C, Yunusoğlu O. Oleanolic acid suppresses pentylenetetrazole-induced seizure in vivo. Int J Environ Health Res. 2023 May;33(5):529-540. doi: 10.1080/09603123.2023.2167947. Epub 2023 Feb 22. PMID: 36812380.
|
Cell experiment [1]: |
|
|
Cell lines |
PLC cells (Peritoneal lymphocytes (PLC-PRF-5)) |
|
Preparation method |
PLC cells (5 × 103 cells/mL) were seeded in 96-well culture plates and incubated for 20 hours. Following this, the cells were treated with either solvent alone, oleanolic acid (at concentrations of 50 μM, 65 μM, and 80 μM), regorafenib, or a combination of oleanolic acid and regorafenib. The cells were then incubated for either 24 hours or 48 hours. |
|
Reaction Conditions |
50, 65, and 80 μM;24/48h |
|
Applications |
Oleanolic acid at doses of 65 μM or 80 μM enhanced the efficacy of regorafenib in suppressing the growth of PLC cells. |
|
Animal experiment [1]: |
|
|
Animal models |
6-8week male BAlB/c nu/nu mice |
|
Preparation method |
1 × 106 PLC cells, suspended in PBS, were subcutaneously injected for inoculation into mice, who were then randomly divided into four groups. Two weeks post-inoculation, the experimental groups were orally administered oleanolic acid (50 mg/kg daily), regorafenib (10 mg/kg daily), or a combination of oleanolic acid (50 mg/kg daily) and regorafenib (10 mg/kg daily) for an additional 2 weeks. The control group received an equivalent volume of saline for the same duration. |
|
Dosage form |
50 mg/kg/d; i.g; 2weeks |
|
Applications |
Oleanolic acid treatment significantly inhibited the tumor growth. It can enhance the antitumor effect of regorafenib. |
|
References: [1].Wang H, Zhong W, et,al. Oleanolic Acid Inhibits Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization. Mol Cancer Ther. 2019 Jan;18(1):62-74. doi: 10.1158/1535-7163.MCT-18-0448. Epub 2018 Oct 8. PMID: 30297361. |
|
| Cas No. | 508-02-1 | SDF | |
| Synonyms | Astrantiagenin C, Caryophyllin, Giganteumgenin C, Gledigenin 1, NSC 114945, Oleanoic Acid, Virgaureagenin B | ||
| Chemical Name | (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid | ||
| Canonical SMILES | CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)O)C | ||
| Formula | C30H48O3 | M.Wt | 456.71 |
| Solubility | ≥ 11.1mg/mL in DMSO | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1896 mL | 10.9479 mL | 21.8957 mL |
| 5 mM | 0.4379 mL | 2.1896 mL | 4.3791 mL |
| 10 mM | 0.219 mL | 1.0948 mL | 2.1896 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *